INSM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Insmed Inc (INSM) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong growth potential, positive analyst sentiment, and upcoming catalysts in 2026. Despite some technical weakness, the long-term outlook and strong fundamentals make it a solid investment opportunity.
The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 21.395, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 144.991), suggesting a potential entry point for long-term investors.
Strong analyst sentiment with multiple Buy and Overweight ratings, and price targets significantly above the current price (e.g., $231 from Barclays, $212 from Roth Capital).
Revenue growth of 52.36% YoY in Q3
Positive outlook for Brinsupri launch and Phase 3 ENCORE study with high success probability.
Biotech sector expected to benefit from M&A activity and strong fundamentals in 2026.
Recent technical indicators show bearish momentum.
Failure of the BiRCH trial for brensocatib in CRSsNP, leading to a valuation reset.
Negative net income and EPS, though improving YoY.
In Q3 2025, revenue increased by 52.36% YoY to $142.34M. Net income improved by 67.79% YoY to -$370.02M. EPS rose by 37.80% YoY to -1.75. Gross margin increased by 3.03% to 78.29%. While the company is not yet profitable, its financials show significant improvement and growth potential.
Analysts are highly positive on Insmed, with multiple Buy and Overweight ratings. Recent price targets range from $157 to $231, indicating strong upside potential. Analysts highlight the company's promising pipeline, expected M&A activity, and strong fundamentals as key drivers for growth in 2026.
